Navigation Links
Protective regimen for acute Graft-versus-host disease

Allogeneic hematopoietic-cell transplantation with the use of conditioning regimens of non-myeloablative radiotherapy, chemotherapy, or both to decrease early toxic effects extends the possibility of hematopoietic-cell// transplantation to patients older than 50 years and those with coexisting conditions.

However, acute graft-versus-host disease (GVHD) remains a major problem after non-myeloablative transplantation. Death due to this complication accounts for approximately 50% of the deaths that are not due to a relapse of the neoplasm.

Conditioning with total lymphoid irradiation plus anti-thymocyte serum has been previously shown to protect mice against acute GVHD after hematopoietic-cell transplantation.

Recently, a research team from the Stanford University School of Medicine, Stanford, California, tested this strategy in humans.

In a study published in the September issue of New England Journal of Medicine, 37 patients with lymphoid malignant diseases or acute leukemia underwent an experimental conditioning regimen with 10 doses of total lymphoid irradiation (80 cGy each) plus antithymocyte globulin, followed by an infusion of HLA-matched peripheral-blood mononuclear cells from related or unrelated donors who received granulocyte colony-stimulating factor.

Of the 37 transplant recipients, only 2 had acute GVHD after hematopoietic-cell transplantation. Potent antitumor effects in patients with lymphoid malignant diseases were shown by the change from partial to complete remission. In the transplant recipients who underwent conditioning with total lymphoid irradiation and antithymocyte globulin, the fraction of donor CD4+ T cells that produced interleukin-4 after in vitro stimulation increased by a factor of five, and the proliferative response to alloantigens in vitro was reduced, as compared with normal control subjects and control subjects who underwent conditioning with a single dose of total-body irradiation (200 cGy).

The study concludes that a regimen of nonmyeloablative conditioning of total lymphoid irradiation plus antithymocyte globulin given before hematopoietic-cell transplantation for lymphoid malignant diseases or acute leukemia can markedly decrease the incidence of acute GVHD while retaining the antitumor effect of the graft, and allows graft antitumor activity in patients with lymphoid malignant diseases or acute leukemia treated with hematopoietic-cell transplantation.
'"/>




Related medicine news :

1. Protective effects of tomatoes in prostate cancer
2. Olive Oil Found To Offer A Protective Effect Against Breast Cancer
3. Bird Flu: Orissa Initiates Protective Measures
4. Skin Cancer Cream Has A Protective Effect On Prematurely Aged Skin?
5. High Demand For Protective Suit in Afghan: Culling Would Have To Wait
6. Protective Protein Could Hold The Key In Fight Against Tuberculosis
7. Antibiotic Proved Protective against Heart Tissue Damage and Cell Death – Research Find
8. Protective Clothing of Health Workers Insufficent Against Contamination
9. Protective Intestinal Antibiotic Protein Discovered
10. Athletic Gear in Youth Not Protective Against Near Fatal Blows to chest
11. Know the Protective Face of the Sun
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...
(Date:12/8/2016)... ... 08, 2016 , ... Vida Health, the digital health platform that ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor ... more consumers who are managing chronic conditions or simply want to improve ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
(Date:12/8/2016)... A Small Business Innovative Research (SBIR) grant ... (NIH) to Phoenix -based NeuroEM Therapeutics, ... grant will seek to determine an optimal set of ... waves to treat Alzheimer,s Disease. The grant will also ... treat other neurologic disorders such as Parkinson,s Disease and ...
(Date:12/8/2016)... New York , December 8, 2016 ... global Diabetes Injection Pens Market is expected to ... compared to US$4.9 bn in 2015. Between the forecast years ... rise at a CAGR of 7.9%. The leading players operating ... A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and ...
Breaking Medicine Technology: